Search results for "Function"

showing 10 items of 14432 documents

Nonroutine Use of Intra-Aortic Balloon Pump in Cardiogenic Shock Complicating Myocardial Infarction With Successful and Unsuccessful Primary Percutan…

2018

Abstract Objectives The authors sought to compare outcomes of patients with myocardial infarction and cardiogenic shock (CS) treated with percutaneous coronary intervention (PCI) with or without intra-aortic balloon pump (IABP) support according to final epicardial flow in the infarct-related artery. Background A routine use of IABP is contraindicated in patients with myocardial infarction and CS. There are no data regarding the subpopulation of patients who may benefit from such support besides patients with mechanical complications of myocardial infarction. Methods Prospective nationwide registry data of patients with myocardial infarction and CS treated with PCI between 2003 and 2014 wer…

medicine.medical_specialtyTime Factorsmedicine.medical_treatmentShock Cardiogenicprimary PCI030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineRisk FactorsInternal medicinemedicineHumansProspective StudiesRegistriescardiovascular diseases030212 general & internal medicineMyocardial infarctionIABPNon-ST Elevated Myocardial InfarctionIntra-aortic balloon pumpIntra-Aortic Balloon Pumpingbusiness.industryCardiogenic shockHazard ratiocardiogenic shockPercutaneous coronary interventionRecovery of FunctionThrombolysismedicine.diseaseTreatment Outcomesurgical procedures operativemyocardial infarctionConventional PCICardiologyST Elevation Myocardial InfarctionPolandCardiology and Cardiovascular MedicinebusinessTIMIJACC-Cardiovascular Interventions
researchProduct

Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.

2021

Aims Despite aortic stenosis (AS) relief, patients undergoing transcatheter aortic valve implantation (TAVI) are at increased risk of developing heart failure (HF) within first months of intervention. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have been shown to reduce the risk of HF hospitalization in individuals with diabetes mellitus (DM), reduced left ventricular ejection fraction (LVEF) and chronic kidney disease (CKD). However, the effect of SGLT-2 inhibitors on outcomes after TAVI is unknown. The Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) trial is designed to assess the clinical benefit and safety of the SGLT-2 inhibitor dapagliflozin in patients …

medicine.medical_specialtyTranscatheter aorticVentricular Function Leftlaw.inventionTranscatheter Aortic Valve Replacementchemistry.chemical_compoundRandomized controlled trialGlucosideslawInternal medicineDiabetes mellitusmedicineHumansProspective StudiesDapagliflozinBenzhydryl CompoundsHeart FailureEjection fractionbusiness.industryStroke VolumeAortic Valve Stenosismedicine.diseaseStenosisTreatment OutcomechemistryHeart failureAortic ValveCardiologyCardiology and Cardiovascular MedicinebusinessKidney diseaseEuropean journal of heart failureReferences
researchProduct

Intensive Care Management of Head-Injured Patient

2019

Traumatic brain injury (TBI) plays an important role for the prognosis of multiple injured patients. Severely injured patients require intensive care treatment to support organ function and to maintain normal brain physiology. Optimal treatment is a cornerstone for good outcome. Therefore, in addition to general principles and concepts of modern intensive care medicine, special brain-specific aspects need to be addressed in these patients. Essential aspects of physiological regulation of cerebral perfusion and intracranial pressure as well as recent publications are reviewed as basis for current trends in the management of TBI patients. Focusing on single parameters such as intracranial pre…

medicine.medical_specialtyTraumatic brain injurybusiness.industryIntensive care managementOrgan functionMultimodal therapymedicine.diseaseCerebral oxygenationmedicineCerebral perfusion pressureIntensive care medicinebusinessIntensive care treatmentIntracranial pressure
researchProduct

Treatment of clinically localized renal tumors in the elderly

2011

There are several options for treating clinically localized renal tumors in the elderly, ranging from active surveillance to radical nephrectomy. Reduced renal function is associated with increased cardiovascular mortality, so maintaining renal function is of the utmost importance. Personalized therapy should be based on tumor location, comorbidities and general health status rather than tumor size and patient age.

medicine.medical_specialtyTumor sizebusiness.industryUrologymedicine.medical_treatmentUrologyRenal functionurologic and male genital diseasesmedicine.diseaseNephrectomymedicineGeneral healthTumor locationPersonalized therapybusinessKidney cancerCardiovascular mortalityNature Reviews Urology
researchProduct

Shared Genetic and Environmental Effects on Strength and Power in Older Female Twins

2005

Purpose: This study examined the relative contribution of genetic and environmental effects on maximal leg extensor power and also investigated whether leg extensor power and maximum voluntary isometric knee extensor strength share a genetic component. Methods: Muscle functions were measured as part of the Finnish Twin Study on Aging in 101 monozygotic (MZ) and 116 dizygotic (DZ) female twin pairs aged 63–76 yr. Leg extensor power was measured using the Nottingham Leg Extensor Power Rig and maximum voluntary isometric knee extensor strength using an adjustable dynamometer chair. The analyses were carried out using the maximum likelihood method in Mx-program on the raw data set. Results: A b…

medicine.medical_specialtyTwinsPhysical Therapy Sports Therapy and RehabilitationIsometric exerciseBiologyCohort StudiesTwins DizygoticmedicineHumansKneeOrthopedics and Sports MedicineExerciseFinlandAgedKnee extensorsDynamometerMusclesTwins MonozygoticMiddle AgedMuscle functionsHeritabilitymusculoskeletal systemTwin studyPower (physics)Environmental effectLower ExtremityPhysical therapyFemaleMedicine & Science in Sports & Exercise
researchProduct

Abstract 412: The Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Improves Diabetic Complications in the Streptozotocin Type 1 Diabetes Mellit…

2014

Objectives: In diabetes, cardiovascular complications are associated with endothelial dysfunction and oxidative stress. Empagliflozin (Empa), as a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i) in clinical development, offers a promising novel approach for the treatment of type 2 diabetes by enhancing urinary glucose excretion. The aim of the present study was to test whether treatment with Empa could improve endothelial dysfunction in type I diabetic rats via reduction of glucotoxicity and associated oxidative stress. Research Design and Methods: Type I diabetes in Wistar rats was induced by an intravenous injection of streptozotocin (60 mg/kg). One week after injection Empa…

medicine.medical_specialtyType 1 diabetesbusiness.industryType 2 diabetesmedicine.diseasemedicine.disease_causeStreptozotocinEndocrinologyInternal medicineDiabetes mellitusmedicineEmpagliflozinEndothelial dysfunctionSGLT2 InhibitorCardiology and Cardiovascular MedicinebusinessOxidative stressmedicine.drugArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

2021

Objective: Radical prostatectomy (RP) is a frequent treatment for men suffering from localized prostate cancer (PCa). Whilst offering a high chance for cure, it does not come without a significant impact on health-related quality of life. Herein we review the common adverse effects RP may have over the course of time.Methods: A collaborative narrative review was performed with the identification of the principal studies on the topic. The search was executed by a relevant term search on PubMed from 2010 to February 2021.Results: Rates of major complications in patients undergoing RP are generally low. The main adverse effects are erectile dysfunction varying from 11 to 87% and urinary incont…

medicine.medical_specialtyUrinary continencebusiness.industryProstatectomymedicine.medical_treatment030232 urology & nephrologyUrinary incontinencemedicine.disease03 medical and health sciencesProstate cancer0302 clinical medicineErectile dysfunctionQuality of life030220 oncology & carcinogenesismedicineSurgeryMajor complicationmedicine.symptomAdverse effectbusinessIntensive care medicineFrontiers in Surgery
researchProduct

Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

2020

Abstract Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal funct…

medicine.medical_specialtyUrologyRenal function030204 cardiovascular system & hematologySacubitril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHeart failure with reduced ejection fraction (HFrEF)Original Research ArticlesRenal safety profileType 2 diabetes mellitusEmpagliflozinDiseases of the circulatory (Cardiovascular) systemMedicineSGLT2iOriginal Research Article030212 general & internal medicineSacubitril/valsartanCreatinineEjection fractionbusiness.industrymedicine.diseasechemistryValsartanRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drugRenal function
researchProduct

A noninvasive postoperative clinical score to identify patients at risk for postoperative pulmonary complications: The air-test score

2020

BACKGROUND: Postoperative pulmonary complications (PPCs) negatively affect morbidity, healthcare costs and postsurgical survival. Preoperative and intraoperative peripheral oxyhemoglobin saturation (SpO2) levels are independent risk factors for postoperative pulmonary complications (PPCs). The air-test assesses the value of SpO2 while breathing room-air. We aimed at building a clinical score that includes the air-test for predicting the risk for PPCs. METHODS: This is a development and validation study in patients -randomly divided into two cohorts- from a large randomized clinical trial (iPROVE) that enrolled 964 intermediate-to-high risk patients scheduled for abdominal surgery. Arterial …

medicine.medical_specialtyValidation studyPulmonary AtelectasisAtelectasisRisk Assessmentlaw.inventionCohort Studies03 medical and health sciencesPostoperative pulmonary atelectasis0302 clinical medicinePostoperative ComplicationsRandomized controlled trial030202 anesthesiologylawRisk FactorsmedicineHumansPredictive value of testDerivationLungReceiver operating characteristicbusiness.industryfungi030208 emergency & critical care medicinemedicine.diseaseSurgeryRespiratory Function TestsPostoperative complicationAnesthesiology and Pain MedicineTest scoreCohortbusinessAbdominal surgery
researchProduct

Safety of agalsidase alfa in patients with Fabry disease under 7 years

2011

Aim:  To evaluate the safety and explore the efficacy of enzyme replacement therapy (ERT) for Fabry disease with agalsidase alfa in young children enrolled in the Fabry Outcome Survey (FOS). Methods:  This retrospective chart review identified eight children (mean age = 5.0 ± 1.6 [mean ± SD]) in FOS who began treatment with agalsidase alfa (0.2 mg/kg, i.v., every other week) when <7 years old. Vital signs and adverse events were monitored throughout the study period. Glomerular filtration rate (GFR) was estimated, and left ventricular mass indexed to height2.7 (LVMi) was assessed with echocardiography. Patients received 1.2–6.7 years of treatment (mean = 4.2 years). Results:  Infusion react…

medicine.medical_specialtyVascular diseasebusiness.industryOrgan dysfunctionVital signsRenal functionRetrospective cohort studyGeneral MedicineEnzyme replacement therapymedicine.diseaseFabry diseaseSurgeryInternal medicinePediatrics Perinatology and Child Healthmedicinemedicine.symptomAdverse effectbusinessActa Paediatrica
researchProduct